User:MBae2/sandbox
From Wikipedia, the free encyclopedia
**COPIED FROM HIV-1 protease*
Quick Facts HIV-1 Protease (Retropepsin), Identifiers ...
HIV-1 Protease (Retropepsin) | |||||||||
---|---|---|---|---|---|---|---|---|---|
![]() HIV-1 protease dimer in white and grey, with peptide substrate in black and active site aspartate side chains in red. (PDB: 1KJF) | |||||||||
Identifiers | |||||||||
EC no. | 3.4.23.16 | ||||||||
CAS no. | 144114-21-6 | ||||||||
Databases | |||||||||
IntEnz | IntEnz view | ||||||||
BRENDA | BRENDA entry | ||||||||
ExPASy | NiceZyme view | ||||||||
KEGG | KEGG entry | ||||||||
MetaCyc | metabolic pathway | ||||||||
PRIAM | profile | ||||||||
PDB structures | RCSB PDB PDBe PDBsum | ||||||||
Gene Ontology | AmiGO / QuickGO | ||||||||
|
Close
HIV-1 protease is a retroviral aspartyl protease (retropepsin) that is essential for the life-cycle of HIV, the retrovirus that causes AIDS.[1][2] HIV protease cleaves newly synthesized polyproteins (namely, Gag and Gag-Pol[3]) at nine cleavage sites to create the mature protein components of an infectious HIV virion.[4] Without effective HIV protease, HIV virions remain uninfectious.[5][6] Thus, mutation of HIV protease's active site or inhibition of its activity disrupts HIV’s ability to replicate and infect additional cells,[7] making HIV protease inhibition the subject of considerable pharmaceutical research. [8]